Phenotype of new daily persistent headache: subtypes and comparison to transformed chronic daily headache.
Chronic daily headache
Disease classification
Migraine
NDPH
Phenotype
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
05
06
2023
accepted:
24
07
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
It is unknown whether new daily persistent headache (NDPH) is a single disorder or heterogenous group of disorders, and whether it is a unique disorder from chronic migraine and chronic tension-type headache. We describe a large group of patients with primary NDPH, compare its phenotype to transformed chronic daily headache (T-CDH), and use cluster analysis to reveal potential sub-phenotypes in the NDPH group. We performed a case-control study using prospectively collected clinical data in patients with primary NDPH and T-CDH (encompassing chronic migraine and chronic tension-type headache). We used logistic regression with propensity score matching to compare demographics, phenotype, comorbidities, and treatment responses between NDPH and T-CDH. We used K-means cluster analysis with Gower distance to identify sub-clusters in the NDPH group based on a combination of demographics, phenotype, and comorbidities. We identified 366 patients with NDPH and 696 with T-CDH who met inclusion criteria. Patients with NDPH were less likely to be female (62.6% vs. 73.3%, p < 0.001). Nausea, vomiting, photophobia, phonophobia, motion sensitivity, vertigo, and cranial autonomic symptoms were all significantly less frequent in NDPH than T-CDH (p value for all < 0.001). Acute treatments appeared less effective in NDPH than T-CDH, and medication overuse was less common (16% vs. 42%, p < 0.001). Response to most classes of oral preventive treatments was poor in both groups. The most effective treatment in NDPH was doselupin in 45.7% patients (95% CI 34.8-56.5%). Cluster analysis identified three subgroups of NDPH. Cluster 1 was older, had a high proportion of male patients, and less severe headaches. Cluster 2 was predominantly female, had severe headaches, and few associated symptoms. Cluster 3 was predominantly female with a high prevalence of migrainous symptoms and headache triggers. Whilst there is overlap in the phenotype of NDPH and T-CDH, the differences in migrainous, cranial autonomic symptoms, and vulnerability to medication overuse suggest that they are not the same disorder. NDPH may be fractionated into three sub-phenotypes, which require further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
It is unknown whether new daily persistent headache (NDPH) is a single disorder or heterogenous group of disorders, and whether it is a unique disorder from chronic migraine and chronic tension-type headache. We describe a large group of patients with primary NDPH, compare its phenotype to transformed chronic daily headache (T-CDH), and use cluster analysis to reveal potential sub-phenotypes in the NDPH group.
METHODS
METHODS
We performed a case-control study using prospectively collected clinical data in patients with primary NDPH and T-CDH (encompassing chronic migraine and chronic tension-type headache). We used logistic regression with propensity score matching to compare demographics, phenotype, comorbidities, and treatment responses between NDPH and T-CDH. We used K-means cluster analysis with Gower distance to identify sub-clusters in the NDPH group based on a combination of demographics, phenotype, and comorbidities.
RESULTS
RESULTS
We identified 366 patients with NDPH and 696 with T-CDH who met inclusion criteria. Patients with NDPH were less likely to be female (62.6% vs. 73.3%, p < 0.001). Nausea, vomiting, photophobia, phonophobia, motion sensitivity, vertigo, and cranial autonomic symptoms were all significantly less frequent in NDPH than T-CDH (p value for all < 0.001). Acute treatments appeared less effective in NDPH than T-CDH, and medication overuse was less common (16% vs. 42%, p < 0.001). Response to most classes of oral preventive treatments was poor in both groups. The most effective treatment in NDPH was doselupin in 45.7% patients (95% CI 34.8-56.5%). Cluster analysis identified three subgroups of NDPH. Cluster 1 was older, had a high proportion of male patients, and less severe headaches. Cluster 2 was predominantly female, had severe headaches, and few associated symptoms. Cluster 3 was predominantly female with a high prevalence of migrainous symptoms and headache triggers.
CONCLUSIONS
CONCLUSIONS
Whilst there is overlap in the phenotype of NDPH and T-CDH, the differences in migrainous, cranial autonomic symptoms, and vulnerability to medication overuse suggest that they are not the same disorder. NDPH may be fractionated into three sub-phenotypes, which require further investigation.
Identifiants
pubmed: 37587430
doi: 10.1186/s10194-023-01639-5
pii: 10.1186/s10194-023-01639-5
pmc: PMC10428606
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Informations de copyright
© 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
Références
J Neurol. 2020 Nov;267(11):3243-3247
pubmed: 32542525
Cephalalgia. 2011 Feb;31(3):301-15
pubmed: 20813784
Am J Med Genet C Semin Med Genet. 2015 Mar;169C(1):84-96
pubmed: 25655119
Headache. 2001 Sep;41(8):830-2
pubmed: 11576211
J Headache Pain. 2022 Jul 22;23(1):86
pubmed: 35869443
Qual Life Res. 2003 Dec;12(8):963-74
pubmed: 14651415
Headache. 1999 Mar;39(3):190-6
pubmed: 15613213
Front Artif Intell. 2022 Aug 12;5:842306
pubmed: 36034597
Neurology. 2011 Nov 15;77(20):1827-32
pubmed: 22049203
Headache. 2011 Apr;51(4):650-3
pubmed: 21457252
Headache. 2021 Nov;61(10):1529-1538
pubmed: 34710236
Headache. 2022 Jul;62(7):828-838
pubmed: 35861031
Cephalalgia. 2022 Apr;42(4-5):385-395
pubmed: 34579562
Cephalalgia. 2023 May;43(5):3331024231168089
pubmed: 37032616
J Headache Pain. 2022 Apr 12;23(1):34
pubmed: 35410119
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Neurology. 2011 Oct 11;77(15):1465-72
pubmed: 21956721
Cephalalgia. 2023 Jan;43(1):3331024221131331
pubmed: 36587297
Brain Commun. 2022 Mar 10;4(3):fcac059
pubmed: 35528230
J Headache Pain. 2020 May 24;21(1):55
pubmed: 32448142
Cephalalgia. 2002 Feb;22(1):66-9
pubmed: 11993616
Neuromodulation. 2021 Aug;24(6):1093-1099
pubmed: 32996695
Cephalalgia. 1999 Mar;19(2):107-14; discussion 74
pubmed: 10214536
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Cephalalgia. 2020 May;40(6):554-564
pubmed: 32102546
Sci Rep. 2021 Feb 15;11(1):3846
pubmed: 33589682
Cephalalgia. 2023 Feb;43(2):3331024221146314
pubmed: 36759317
Cephalalgia. 2020 Sep;40(10):1063-1069
pubmed: 32336121
J Neurol Neurosurg Psychiatry. 2002 Jun;72 Suppl 2:ii6-ii9
pubmed: 12122194
Cephalalgia. 2006 Oct;26(10):1182-5
pubmed: 16961783
Sci Rep. 2020 Feb 18;10(1):2804
pubmed: 32071349
Neurol Sci. 2022 Jan;43(1):541-547
pubmed: 33991261